FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., Creemers, G.-J. M., van Dam, R. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02274 · Cited by 1,082
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Versteijne, E., van Dam, J. L., Suker, M., Janssen, Q. P., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02233 · Cited by 786
“Pancreas body and tail resection 12/119 (10) 8/127 (6)”
BackgroundBiliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
“14,60 To decide whether further resection is necessary in incidentally diagnosed GBC, staging is required with appropriate imaging (MRI or CT) and detailed histopathological analysis, including T stage, cystic duct margin, involvement of resected lymph nodes, grade and perineural and/or Purple:…”
BackgroundSelf-citationRole of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Self-citationChemoresistance in Pancreatic Cancer
Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C., & Yang, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184504 · Cited by 611
Accurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
“In particular, we investigated the prevalence of druggable fusions, because there are few targeted treatment options for pancreatic cancer patients, and despite recent improvements in conventional and targeted therapies (Conroy et al. 2018; Golan et al. 2019), the 5-yr overall survival rate is <10%.”
BackgroundStoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot, J., Xu, Y., Lesker, T. R., Schönlein, M., Konczalla, L., Giannou, A. D., Pelczar, P., Kylies, D., Puelles, V. G., Bielecka, A. A., et al. (2023) · Nature · doi:10.1038/s41586-023-05728-y · Cited by 478
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01169-7 · Cited by 413
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M., & Garrido-Laguna, I. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 393
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S., Wright, G. P., & Chung, M. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 386
“PRODIGE 24 was a large multi-national phase 3 trial comparing modified FOLFIRINOX regimen (reduced irinotecan and no bolus 5-FU) to gemcitabine in the adjuvant setting [62].”
Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370
Zhou, C., Yi, C., Yi, Y., Qin, W., Yan, Y., Dong, X., Zhang, X., Huang, Y., Zhang, R., Wei, J., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01237-y · Cited by 382
“Although in recent clinical trials combinations of gemcitabine with other drugs resulted in relative improvements in median survival time, unfortunately, gemcitabine failed to significantly improve the overall prognosis and survival rates of pancreatic cancer patients, which was mainly caused by natural and/or acquire…”
BackgroundNeoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
“, 5-fluorouracil (5-FU), leucovorin, oxaliplatin, and irinotecan) and nab-paclitaxel plus gemcitabine are generally considered as the best adjuvant chemotherapy regimens, although they have shown only modest survival benefits with considerable toxicity.(13) Furthermore, multiple novel-targeted therapies (i.”
BackgroundGuidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Tempero, M. A., Malafa, M. P., Chiorean, E. G., Czito, B., Scaife, C., Narang, A. K., Fountzilas, C., Wolpin, B. M., Al-Hawary, M., Asbun, H., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0014 · Cited by 367
Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3829 · Cited by 344
Self-citationGATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3724 · Cited by 352
Self-citationGhaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00348-x · Cited by 337
“9,10,15,16 We might speculate that chemotherapy is more tolerable with less toxicity before surgery than after resection.”
BackgroundMicroenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Sohal, D. P. S., Duong, M., Ahmad, S. A., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7328 · Cited by 302
Janssen, Q. P., Buettner, S., Suker, M., Beumer, B. R., Addeo, P., Bachellier, P., Bahary, N., Bekaii-Saab, T., Bali, M. A., Besselink, M. G., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz073 · Cited by 297
Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer
Li, Y.-J., Wu, J.-Y., Wang, J.-M., Hu, X.-B., Cai, J.-X., & Xiang, D.-X. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.10.022 · Cited by 291
Cui Zhou, D., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 284
Jones, R. P., Psarelli, E.-E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., Campbell, F., Valle, J. W., Faluyi, O., O’Reilly, D. A., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.3337 · Cited by 274
Self-citationPrincipe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 250
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250
“Given the complex immunosuppressive landscape of the PDAC microenvironment143–145, we will focus here on immune targeting strategies with three primary aims: (1) removing short-lived immunosuppressive myeloid cells; (2) reprogramming dendritic cells (DCs) to better prime tumor-specific T cell responses, particularly i…”
BackgroundThe Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alashkar Alhamwe, B., von Strandmann, E., Slater, E. P., Bartsch, J. W., Bauer, C., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 244
“Recently, the survival of patients with resectable tumors was shown to be significantly improved by neoadjuvant radiochemotherapy [5] and to an impressive 54-month median overall survival with adjuvant FOLFIRINOX chemotherapy [6].”
BackgroundAhmad, S. A., Duong, M., Sohal, D. P. S., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004155 · Cited by 238
“Annals of Surgery Volume 272, Number 3, September 2020 P rospective clinical trials have validated adjuvant therapy as a treatment modality that improves overall survival (OS) in patients with resectable pancreas cancer.(1,2) Unfortunately, the great majority of patients with pancreas cancer have occult systemic disea…”
Backgroundvan Dam, J. L., Janssen, Q. P., Besselink, M. G., Homs, M. Y. V., van Santvoort, H. C., van Tienhoven, G., de Wilde, R. F., Wilmink, J. W., van Eijck, C. H. J., & Groot Koerkamp, B. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.023 · Cited by 232
Sun, X., He, X., Zhang, Y., Hosaka, K., Andersson, P., Wu, J., Wu, J., Jing, X., Du, Q., Hui, X., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322744 · Cited by 233
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Labori, K. J., Bratlie, S. O., Andersson, B., Angelsen, J.-H., Biörserud, C., Björnsson, B., Bringeland, E. A., Elander, N., Garresori, H., Grønbech, J. E., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00405-3 · Cited by 225
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05351-1 · Cited by 214
“In contrast, a small subset of PDAC patients with resectable tumours had improved survival after receiving modified FOLFIRINOX (excluding 5-fluorouracil) [5, 6].”
ResultNeoadjuvant Treatment in Pancreatic Cancer
Oba, A., Ho, F., Bao, Q. R., Al-Musawi, M. H., Schulick, R. D., & Del Chiaro, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00245 · Cited by 216
Lee, B., Lipton, L., Cohen, J., Tie, J., Javed, A. A., Li, L., Goldstein, D., Burge, M., Cooray, P., Nagrial, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz200 · Cited by 215
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Van Laethem, J.-L., Malka, D., Ducreux, M., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 211
Self-citationThe pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Groot, V. P., Mosier, S., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0197 · Cited by 208
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update
Khorana, A. A., McKernin, S. E., Berlin, J., Hong, T. S., Maitra, A., Moravek, C., Mumber, M., Schulick, R., Zeh, H. J., & Katz, M. H. G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00946 · Cited by 206
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, E., Kude de Almeida, F., Baptista Simões, C., Wiesmüller, L., Seufferlein, T., & Kleger, A. (2021) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 206
Stoop, T. F., Theijse, R. T., Seelen, L. W. F., Groot Koerkamp, B., van Eijck, C. H. J., Wolfgang, C. L., van Tienhoven, G., van Santvoort, H. C., Molenaar, I. Q., Wilmink, J. W., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00856-2 · Cited by 201
“In patients with BRPC or LAPC, an upfront surgical resection is considered suboptimal and is associated with poor survival 6–8 , even in patients receiving adjuvant chemotherapy 9,10 .”
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 197
“non-small cell lung cancer (9), colorectal cancer (10) breast cancer (11), mesothelioma (12) and pancreatic cancer (13)]; a complete response followed by progression [e.”
BackgroundMGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells
Kuang, F., Liu, J., Xie, Y., Tang, D., & Kang, R. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.01.006 · Cited by 199
Pancreatic cancer treatment: better, but a long way to go
Torphy, R. J., Fujiwara, Y., & Schulick, R. D. (2020) · Surgery Today · doi:10.1007/s00595-020-02028-0 · Cited by 197
“4 months in the modified FOLFIRINOX group [26].”
BackgroundRadiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Palta, M., Godfrey, D., Goodman, K. A., Hoffe, S., Dawson, L. A., Dessert, D., Hall, W. A., Herman, J. M., Khorana, A. A., Merchant, N., et al. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.06.016 · Cited by 190
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
Latenstein, A. E. J., van der Geest, L. G. M., Bonsing, B. A., Groot Koerkamp, B., Haj Mohammad, N., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.002 · Cited by 185
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Perri, G., Prakash, L., Qiao, W., Varadhachary, G. R., Wolff, R., Fogelman, D., Overman, M., Pant, S., Javle, M., Koay, E. J., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.2286 · Cited by 174
for the Dutch Pancreatic Cancer Group, Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08031-z · Cited by 169
“6 trial) when compared to gemcitabine monotherapy in the adjuvant setting [5, 27].”
BackgroundNakamura, K., Zhu, Z., Roy, S., Jun, E., Han, H., Munoz, R. M., Nishiwada, S., Sharma, G., Cridebring, D., Zenhausern, F., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.090 · Cited by 166
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
He, S., Dong, G., Li, Y., Wu, S., Wang, W., & Sheng, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915896 · Cited by 167
Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0841 · Cited by 164
“Standard-of-care cytotoxic therapies extend life expectancy only modestly (3,4), thus new therapeutic combinations are urgently needed.”
BackgroundTargeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Dreyer, S. B., Upstill-Goddard, R., Paulus-Hock, V., Paris, C., Lampraki, E.-M., Dray, E., Serrels, B., Caligiuri, G., Rebus, S., Plenker, D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.043 · Cited by 163
Väyrynen, S. A., Zhang, J., Yuan, C., Väyrynen, J. P., Dias Costa, A., Williams, H., Morales-Oyarvide, V., Lau, M. C., Rubinson, D. A., Dunne, R. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3141 · Cited by 160
Macedo, F. I. B., Ryon, E. L., Maithel, S. K., Lee, R. M., Kooby, D. A., Fields, R. C., Hawkins, W. G., Williams, G., Maduekwe, U. N., Kim, H. J., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003468 · Cited by 163
Diabetes, weight change, and pancreatic cancer risk
Yuan, C., Babic, A., Khalaf, N., Nowak, J. A., Brais, L. K., Rubinson, D. A., Ng, K., Aguirre, A. J., Pandharipande, P. V., Fuchs, C. S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2948 · Cited by 150
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150
Strobel, O., Lorenz, P., Hinz, U., Gaida, M. M., König, A., Hank, T. P., Niesen, W., Kaiser, J., Al‐Saeedi, M., Bergmann, F., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004147 · Cited by 152
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Tempero, M. A., Pelzer, U., O'Reilly, E. M., Winter, J. M., Oh, D., Li, C., Tortora, G., Chang, H.-M., Lopez, C. D., Bekaii‐Saab, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01134 · Cited by 158
“Europe 203 (47) 205 (47) 408 (47) Australia 30 (7) 20 (5) 50 (6) Asia Pacific 55 (13) 53 (12) 108 (12)”
Self-citationCloyd, J. M., Heh, V., Pawlik, T. M., Ejaz, A. M., Dillhoff, M. E., Tsung, A., Williams, T. M., Abushahin, L. I., Bridges, J. F. P., & Santry, H. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041129 · Cited by 153
Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States
Tavakkoli, A., Singal, A. G., Waljee, A. K., Elmunzer, B. J., Pruitt, S. L., McKey, T. A., Rubenstein, J. H., Scheiman, J. M., & Murphy, C. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.059 · Cited by 145
van Roessel, S. R., van Veldhuisen, E., Klompmaker, S., Janssen, Q. P., Hilal, M. A., Alseidi, A. A., Balduzzi, A., Balzano, G., Bassi, C., Berrevoet, F. C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3537 · Cited by 143
Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
Haque, M. R., Wessel, C. R., Leary, D. D., Wang, C., Bhushan, A., & Bishehsari, F. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00370-6 · Cited by 137
D'Angelica, M. I., Ellis, R. J., Liu, J. B., Brajcich, B. C., Gönen, M., Thompson, V. M., Cohen, M. E., Seo, S. K., Zabor, E. C., Babicky, M. L., et al. (2023) · JAMA · doi:10.1001/jama.2023.5728 · Cited by 137
Liu, X., Jiang, J., Liao, Y., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., Ji, Y. C., Mei, K., et al. (2021) · Advanced Science · doi:10.1002/advs.202002147 · Cited by 133
Periarterial divestment in pancreatic cancer surgery
Diener, M. K., Mihaljević, A. L., Strobel, O., Loos, M., Schmidt, T., Schneider, M. A., Berchtold, C., Mehrabi, A., Müller-Stich, B. P., Jiang, K., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.08.030 · Cited by 131
FOXM1: A small fox that makes more tracks for cancer progression and metastasis
Khan, M. A., Κhan, P., Ahmad, A., Fatima, M., & Nasser, M. W. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.007 · Cited by 133
Yang, Z., Lariviere, M. J., Ko, J., Till, J. E., Christensen, T. E., Yee, S. S., Black, T. A., Tien, K., Lin, A. A., Shen, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3313 · Cited by 136
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 148
Altman, A. M., Wirth, K. M., Marmor, S., Lou, E., Chang, K., Hui, J. Y. C., Tuttle, T. M., Jensen, E. H., & Denbo, J. W. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07602-6 · Cited by 125
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 136
Principe, D. R., Narbutis, M., Kumar, S., Park, A. J., Viswakarma, N., Dorman, M. J., Kamath, S. D., Grippo, P. J., Fishel, M. L., Hwang, R. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2959 · Cited by 134
Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
Gzil, A., Zarębska, I., Bursiewicz, W., Antosik, P., Grzanka, D., & Szylberg, Ł. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05058-1 · Cited by 124
Mackay, T. M., Smits, F. J., Roos, D., Bonsing, B. A., Bosscha, K. P., Busch, O. R., Creemers, G., van Dam, R. M., van Eijck, C. H. J., Gerhards, M. F., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.06.019 · Cited by 126
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 137
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 143
“Modified (m)FOLFIRINOX was further obtained by removing the 5-fluorouracil bolus from the regimen and became the preferred adjuvant therapy for patients with PDAC who had undergone surgical resection and had not received neoadjuvant chemotherapy [9].”
MethodPusceddu, S., Ghidini, M., Torchio, M., Corti, F., Tomasello, G., Niger, M., Prinzi, N., Nichetti, F., Coinu, A., Bartolomeo, M. D., et al. (2019) · Cancers · doi:10.3390/cancers11040484 · Cited by 122
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 127
Why is pancreatic cancer so deadly? The pathologist's view
Hruban, R. H., Gaida, M. M., Thompson, E., Hong, S., Noë, M., Brosens, L. A., Jongepier, M., Offerhaus, G. J. A., & Wood, L. D. (2019) · The Journal of Pathology · doi:10.1002/path.5260 · Cited by 115
Jiang, X., Ma, Y., Wang, T., Zhou, H., Wang, K., Shi, W., Qin, L., Guan, J., Li, L., Long, B., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.025 · Cited by 116
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy
Canè, S., Barouni, R. M., Fabbi, M., Cuozzo, J. W., Fracasso, G., Adamo, A., Ugel, S., Trovato, R., Sanctis, F. D., Giacca, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6221 · Cited by 127
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 161
Yamaguchi, J., Yokoyama, Y., Fujii, T., Yamada, S., Takami, H., Kawashima, H., Ohno, E., Ishikawa, T., Maeda, O., Ogawa, H., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005430 · Cited by 122
“Inclusion criteria included (1) a diagnosis of borderline-resectable pancreatic cancer; (2) no distant metastasis; (3) age between 20 and 75; (4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (5) no other treatment for the disease; (6) no other simultaneous malignancies; (7) no major organ fa…”
BackgroundA detailed insight of the tumor targeting using nanocarrier drug delivery system
Batool, S., Sohail, S., Din, F. U., Alamri, A. H., Alqahtani, A. S., Alshahrani, M. A., Alshehri, M. A. S., & Choi, H. G. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2183815 · Cited by 125
Liu, X., Tang, R., Xu, J., Tan, Z., Liang, C., Meng, Q., Lei, Y., Hua, J., Zhang, Y., Liu, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-329349 · Cited by 126
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.